QSAR studies of the bioactivity of hepatitis C virus (HCV) NS3/4A protease inhibitors by multiple linear regression (MLR) and support vector machine (SVM)

被引:17
|
作者
Qin, Zijian [1 ]
Wang, Maolin [1 ]
Yan, Aixia [1 ]
机构
[1] Beijing Univ Chem Technol, Dept Pharmaceut Engn, State Key Lab Chem Resource Engn, POB 53,15 BeiSanHuan East Rd, Beijing 100029, Peoples R China
基金
中国国家自然科学基金;
关键词
Hepatitis C virus (HCV) NS3/4A protease inhibitors; Quantitative structure-activity relationship (QSAR); Kohonen's self-organizing map (SOM); Multiple linear regression (MLR); Support vector machine (SVM); Sub-dataset analysis; PEPTIDE-BASED INHIBITORS; ALPHA-KETOAMIDES; SERINE-PROTEASE; ANTIVIRAL ACTIVITY; POTENT INHIBITORS; CRYSTAL-STRUCTURE; DISCOVERY; DESIGN; PROTEINASE; BINDING;
D O I
10.1016/j.bmcl.2017.05.001
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In this study, quantitative structure-activity relationship (QSAR) models using various descriptor sets and training/test set selection methods were explored to predict the bioactivity of hepatitis C virus (HCV) NS3/4A protease inhibitors by using a multiple linear regression (MLR) and a support vector machine (SVM) method. 512 HCV NS3/4A protease inhibitors and their IC50 values which were determined by the same FRET assay were collected from the reported literature to build a dataset. All the inhibitors were represented with selected nine global and 12 2D property-weighted autocorrelation descriptors calculated from the program CORINA Symphony. The dataset was divided into a training set and a test set by a random and a Kohonen's self-organizing map (SOM) method. The correlation coefficients (r(2)) of training sets and test sets were 0.75 and 0.72 for the best MLR model, 0.87 and 0.85 for the best SVM model, respectively. In addition, a series of sub-dataset models were also developed. The performances of all the best sub-dataset models were better than those of the whole dataset models. We believe that the combination of the best sub-and whole dataset SVM models can be used as reliable lead designing tools for new NS3/4A protease inhibitors scaffolds in a drug discovery pipeline. (C) 2017 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2931 / 2938
页数:8
相关论文
共 50 条
  • [21] Treatment of HCV infection with the novel NS3/4A protease inhibitors
    De Luca, Andrea
    Bianco, Claudia
    Rossetti, Barbara
    CURRENT OPINION IN PHARMACOLOGY, 2014, 18 : 9 - 17
  • [22] Protease Inhibitors Block Multiple Functions of the NS3/4A Protease-Helicase during the Hepatitis C Virus Life Cycle
    McGivern, David R.
    Masaki, Takahiro
    Lovell, William
    Hamlett, Chris
    Saalau-Bethell, Susanne
    Grahamc, Brent
    JOURNAL OF VIROLOGY, 2015, 89 (10) : 5362 - 5370
  • [23] Identification of Novel Small Molecule Inhibitors Against the NS3/4A Protease of Hepatitis C Virus Genotype 4a
    El-Sayed, Sara M.
    Ali, Mohamed A. M.
    El-Gendy, Bahaa El-Dien M.
    Dandash, Samar S.
    Issac, Yvette
    Saad, Reda
    Azab, Mohamed M.
    Mohamed, Mohamed R.
    CURRENT PHARMACEUTICAL DESIGN, 2018, 24 (37) : 4484 - 4491
  • [24] Inhibitors of hepatitis C virus NS3•4A protease 2.: Warhead SAR and optimization
    Perni, RB
    Pitlik, J
    Britt, SD
    Court, JJ
    Courtney, LF
    Deininger, DD
    Farmer, LJ
    Gates, CA
    Harbeson, SL
    Levin, RB
    Lin, C
    Lin, K
    Moon, YC
    Luong, YP
    O'Malley, ET
    Rao, BG
    Thomson, JA
    Tung, RD
    Van Drie, JH
    Wei, YY
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (06) : 1441 - 1446
  • [25] The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors
    Romano, Keith P.
    Ali, Akbar
    Aydin, Cihan
    Soumana, Djade
    Oezen, Ayseguel
    Deveau, Laura M.
    Silver, Casey
    Cao, Hong
    Newton, Alicia
    Petropoulos, Christos J.
    Huang, Wei
    Schiffer, Celia A.
    PLOS PATHOGENS, 2012, 8 (07) : 22
  • [26] Virtual Screening of Telaprevir and Danoprevir Derivatives for Hepatitis C Virus NS3/4A Protease Inhibitors
    Sarkar, Kaushik
    Das, Rajesh Kumar
    LETTERS IN DRUG DESIGN & DISCOVERY, 2024, 21 (04) : 809 - 822
  • [27] Inhibitors of hepatitis C virus NS3•4A protease:: P2 proline variants
    Farmer, LJ
    Britt, SD
    Cottrell, KM
    Court, JJ
    Courtney, LF
    Deininger, DD
    Gates, CA
    Harbeson, SL
    Lin, K
    Lin, C
    Luong, YP
    Maxwell, JP
    Pitlik, J
    Rao, BG
    Schairer, WC
    Thomson, JA
    Tung, RD
    Van Drie, JH
    Wei, YY
    Perni, RB
    LETTERS IN DRUG DESIGN & DISCOVERY, 2005, 2 (07) : 497 - 502
  • [28] Key Binding and Susceptibility of NS3/4A Serine Protease Inhibitors against Hepatitis C Virus
    Meeprasert, Arthitaya
    Hannongbua, Supot
    Rungrotmongkol, Thanyada
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2014, 54 (04) : 1208 - 1217
  • [29] Inhibitors of hepatitis C virus NS3/4A: α-Ketoamide based macrocyclic inhibitors
    Avolio, Salvatore
    Robertson, Keith
    Hernando, Jose Ignacio Martin
    DiMuzio, Jillian
    Summa, Vincenzo
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (08) : 2295 - 2298
  • [30] Telaprevir: A Hepatitis C NS3/4A Protease Inhibitor
    Matthews, Samuel James
    Lancaster, Jason W.
    CLINICAL THERAPEUTICS, 2012, 34 (09) : 1857 - 1882